Editas Medicine Inc
NASDAQ:EDIT
EV/GP
Enterprise Value to Gross Profit
Market Cap | EV/GP | ||||
---|---|---|---|---|---|
US |
Editas Medicine Inc
NASDAQ:EDIT
|
463.6m USD | 0 | ||
US |
Abbvie Inc
NYSE:ABBV
|
289.2B USD | 9.1 | ||
US |
Amgen Inc
NASDAQ:AMGN
|
166.7B USD | 11.1 | ||
US |
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.7B USD | 7.3 | ||
US |
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.4B USD | 10.7 | ||
AU |
CSL Ltd
ASX:CSL
|
133.2B AUD | 13.4 | ||
US |
Gilead Sciences Inc
NASDAQ:GILD
|
80.7B USD | 3.7 | ||
US |
Moderna Inc
NASDAQ:MRNA
|
47.8B USD | 18.4 | ||
US |
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 24.2 | ||
US |
Biogen Inc
NASDAQ:BIIB
|
31.7B USD | 5.1 | ||
KR |
Celltrion Inc
KRX:068270
|
39.2T KRW | 38.2 |
EV/GP Forward Multiples
Forward EV/GP multiple is a version of the EV/GP ratio that uses forecasted gross profit for the EV/GP calculation. 1-Year, 2-Years, and 3-Years forwards use gross profit forecasts for 1, 2, and 3 years ahead, respectively.